<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0"><channel><title>Individual feed for http://feeds.benzinga.com/benzinga</title><link>http://feeds.benzinga.com/benzinga</link><description>Individual feed output.</description><lastBuildDate>Mon, 05 Jan 2026 11:01:09 GMT</lastBuildDate><generator>PyRSS2Gen-1.1.0</generator><docs>http://blogs.law.harvard.edu/tech/rss</docs><item><title>Here's How Much $1000 Invested In Synopsys 10 Years Ago Would Be Worth Today</title><link>https://www.benzinga.com/insights/news/26/01/49696638/heres-how-much-1000-invested-in-synopsys-10-years-ago-would-be-worth-today</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture6.png</image_url><description>read more</description><pubDate>Mon, 05 Jan 2026 15:45:18 GMT</pubDate></item><item><title>Why This Enphase Energy Analyst Is No Longer Bearish</title><link>https://www.benzinga.com/analyst-stock-ratings/upgrades/26/01/49696285/why-this-enphase-energy-analyst-is-no-longer-bearish</link><image_url>https://cdn.benzinga.com/files/images/story/2026/01/05/Konskie--Poland---January-21--2024-Enpha.jpeg?optimize=medium&amp;dpr=1&amp;auto=webp&amp;height=675&amp;width=1200&amp;fit=crop</image_url><description>KeyBanc Capital Markets upgraded ENPH stock from Underweight to Sector Weight due to potential upside catalysts. Shares have underperformed S&amp;P 500. L...</description><pubDate>Mon, 05 Jan 2026 15:37:33 GMT</pubDate></item><item><title>Here's How Much You Would Have Made Owning S&amp;P Global Stock In The Last 10 Years</title><link>https://www.benzinga.com/insights/news/26/01/49695953/heres-how-much-you-would-have-made-owning-s-p-global-stock-in-the-last-10-years</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture10.png</image_url><description>read more</description><pubDate>Mon, 05 Jan 2026 15:30:27 GMT</pubDate></item><item><title>Constellation Brands Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</title><link>https://www.benzinga.com/analyst-stock-ratings/price-target/26/01/49695895/constellation-brands-earnings-are-imminent-these-most-accurate-analysts-revise</link><image_url>https://cdn.benzinga.com/files/images/story/2026/01/05/Stuttgart--Germany---10-02-2022-Mobile-P.jpeg?optimize=medium&amp;dpr=1&amp;auto=webp&amp;height=675&amp;width=1200&amp;fit=crop</image_url><description>Latest Ratings for STZ Date Firm Action From To Feb 2022 Wells Fargo Maintains Overweight Jan 2022 Barclays Maintains Overweight Jan 2022 Credit Suiss...</description><pubDate>Mon, 05 Jan 2026 15:29:01 GMT</pubDate></item><item><title>Zenas BioPharma Touts Phase 3 Win, But Stock Crashes</title><link>https://www.benzinga.com/news/health-care/26/01/49695599/zenas-biopharma-touts-phase-3-win-but-stock-crashes</link><image_url>https://cdn.benzinga.com/files/images/story/2026/01/05/Scientist-Researcher-Using-Microscope-In.jpeg?optimize=medium&amp;dpr=1&amp;auto=webp&amp;height=675&amp;width=1200&amp;fit=crop</image_url><description>Zenas BioPharma shares fall after Phase 3 obexelimab data in IgG4-RD showed a 56% flare risk reduction, as investors weigh competition from Amgen's FD...</description><pubDate>Mon, 05 Jan 2026 15:21:25 GMT</pubDate></item></channel></rss>